Moderna (MRNA.US) and Merck (MRK.US) are gearing up to launch the first phase 3 trial of an mRNA-based cancer vaccine after studies showed it could be used to treat a malignant type of skin cancer.
Data released by Moderna on Tuesday showed that the combination of the company's experimental cancer vaccine and Merck's immunotherapy drug Keytruda reduced the risk of death or recurrence of melanoma for the group of high-risk patients by 44% compared with only Keytruda treatment.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appThe phase 2 study involved 157 patients who had already undergone surgery for melanoma and were supervised by doctors for a year. Some participants received nine doses of the cancer vaccine codenamed mRNA-4157/V940 combined with Keytruda. Others were given Keytruda alone, which is the standard treatment for high-risk melanoma.
Stéphane Bancel, CEO of Moderna, said the results encouraged Merck and Moderna to launch a more advanced Phase 3 trial, which regulators usually require before approving a new treatment.
Moderna shares rose as much as 25% to $207.37 in premarket trading after the results were announced.
Researchers have long explored the potential of using mRNA technology - which is best known for its use in Covid-19 vaccines - to create a vaccine that instructs the body's immune system how to identify cancerous tumors.
Jeffrey Weber, the study's principal investigator and associate director of the Perlmutter Cancer Center at NYU Langone, said the results provided the first evidence that a personalized neoantigen vaccine approach could be beneficial in cases of melanoma.
However, some analysts urge caution, saying Moderna has only published a small range of trial results that have not yet been verified by independent scientists.
The clinical trial is part of a six-year partnership between Merck and Moderna which aims to develop personalized cancer vaccines. In October, Merck agreed to pay Moderna $250 million to exercise an option to jointly develop and commercialize mRNA-4157/V940 vaccine.
Dean Li, president of Merck Research Laboratories, said the positive study results represent an important milestone in the company's partnership with Moderna.
Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
